Amgen Inc. $AMGN Shares Sold by Bokf Na

Key Points

• Bokf Na reduced its Amgen stake by 3.6% in the third quarter, selling 2,437 shares and retaining 65,040 shares valued at approximately $27.4 million. Institutional investors and hedge funds collectively own 76.5% of Amgen.
• Analyst sentiment remains mixed: Amgen has a consensus “Hold” rating and an average price target of $389.71, despite several firms raising targets and UBS maintaining a Buy rating.
• Amgen reported quarterly earnings and revenue above estimates, while declaring a quarterly dividend of $2.52 per share—a $10.08 annualized payout yielding about 2.2%. Shares recently traded near their 12-month high, but the company faces pricing pressure, biosimilar competition and regulatory scrutiny.

Bokf Na reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 3.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 65,040 shares of the medical research company's stock after selling 2,437 shares during the quarter. Bokf Na's holdings in Amgen were worth $27,415,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. State Street Corp raised its position in shares of Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company's stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares during the period. Bank of America Corp DE acquired a new stake in shares of Amgen during the second quarter valued at approximately $1,831,903,000. Wellington Management Group LLP lifted its position in shares of Amgen by 1,102.7% in the 2nd quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company's stock valued at $993,031,000 after acquiring an additional 2,514,254 shares in the last quarter. BlackRock Inc. lifted its position in shares of Amgen by 4.8% in the 2nd quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock valued at $17,874,974,000 after acquiring an additional 2,261,544 shares in the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of Amgen by 702.8% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company's stock valued at $647,126,000 after acquiring an additional 1,344,010 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on AMGN shares. UBS Group lifted their price target on Amgen from $430.00 to $470.00 and gave the company a "buy" rating in a report on Friday, October 9th. Mizuho boosted their target price on shares of Amgen from $303.00 to $352.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 18th. HSBC downgraded shares of Amgen from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $445.00 to $425.00 in a report on Thursday, September 10th. Barclays raised their price target on shares of Amgen from $380.00 to $400.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 21st. Finally, Cantor Fitzgerald lifted their price target on shares of Amgen from $400.00 to $440.00 and gave the company a "neutral" rating in a report on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Amgen currently has a consensus rating of "Hold" and a consensus price target of $389.71.

Insider Activity

In related news, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president owned 6,404 shares of the company's stock, valued at approximately $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company's stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 in the last 90 days. 0.85% of the stock is owned by corporate insiders.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported positive Phase 3 OASIZ-301 results for dazodalibep in Sjögren’s disease, showing statistically significant and clinically meaningful improvements in systemic disease activity and patient-reported dryness. The company will also present additional data for UPLIZNA, KRYSTEXXA and TAVNEOS, reinforcing the potential of its rare-disease and autoimmune pipeline. Amgen autoimmune disease data announcement
• Positive Sentiment: Goldman Sachs and TD Cowen reiterated Buy ratings, supporting the view that Amgen’s oncology, rare-disease and autoimmune portfolio can sustain growth. Goldman Sachs Buy rating TD Cowen Buy rating
• Positive Sentiment: Amgen declared a quarterly dividend of $2.52 per share, or $10.08 annualized, providing continued income support for shareholders. The payment is scheduled for December 11 to shareholders of record on November 20. Amgen fourth-quarter dividend announcement
• Neutral Sentiment: Amgen will release third-quarter 2026 results after the U.S. market closes on November 3. The company has a four-quarter earnings-beat streak, but investors are focused on whether strong drug sales can offset pricing pressure, biosimilar competition and rising costs. Amgen third-quarter 2026 earnings webcast
• Negative Sentiment: The FDA issued a warning concerning promotional material for Amgen’s cancer drug Vectibix, creating regulatory and compliance risk. FDA warning over Vectibix promotion
• Negative Sentiment: Jefferies raised its price target to $428, which remains below the stock’s recently cited trading level and may signal limited near-term upside despite maintaining broader bullish sentiment. Jefferies Amgen price target

Amgen Stock Performance

Shares of AMGN stock opened at $451.83 on Thursday. The company's fifty day simple moving average is $418.95 and its 200-day simple moving average is $373.41. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a market cap of $244.27 billion, a PE ratio of 28.08, a P/E/G ratio of 3.21 and a beta of 0.41. Amgen Inc. has a 12 month low of $288.00 and a 12 month high of $454.66.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. During the same period in the previous year, the business earned $6.02 EPS. The company's revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts expect that Amgen Inc. will post 22.96 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a $2.52 dividend. The ex-dividend date is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. Amgen's dividend payout ratio (DPR) is presently 62.65%.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.